AVITA MED INC CDI (AVHHL) Financials

AVITA MED INC CDI (AVHHL) reported diluted earnings per share of -$1.74 for fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

AVITA MED INC CDI (AVHHL) had EBITDA of -$40.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

As of fiscal year 2025, AVITA MED INC CDI (AVHHL) had $10.2M in cash and equivalents against $0 in long-term debt.

AVITA MED INC CDI (AVHHL) had a gross margin of 82.1% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

AVITA MED INC CDI (AVHHL) had an operating margin of -59.4% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

AVITA MED INC CDI (AVHHL) had a net profit margin of -67.8% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

AVITA MED INC CDI (AVHHL) recorded an outflow of $32.2M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

AVITA MED INC CDI (AVHHL) recorded an outflow of $31.2M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

AVITA MED INC CDI (AVHHL) had $56.4M in total assets as of fiscal year 2025, including both current and long-term assets.

AVITA MED INC CDI (AVHHL) invested $1.0M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

AVITA MED INC CDI (AVHHL) invested $20.8M in research and development during fiscal year 2025.

AVITA MED INC CDI (AVHHL) had 31M shares outstanding as of fiscal year 2025.

AVITA MED INC CDI (AVHHL) had a current ratio of 0.57 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

AVITA MED INC CDI (AVHHL) had a return on assets of -86.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

AVITA MED INC CDI (AVHHL) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $347.9M as of Oct 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

AVITA MED INC CDI (AVHHL) trades at 4.6x sales, its market capitalization divided by $75.6M revenue, trailing 12 months to June 30, 2026. The market capitalization is $347.9M as of Oct 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

At the end of fiscal year 2025, AVITA MED INC CDI (AVHHL) held $18.2M in cash, cash equivalents and investments, and reported an operating cash outflow of $31.2M over that year. Dividing the one by the other, the reported balance equals about 7 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

AVITA MED INC CDI (AVHHL) has negative shareholder equity of -$16.6M as of fiscal year 2025, so no debt-to-equity or liabilities-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

AVITA MED INC CDI (AVHHL) has an Altman Z-Score of -9.08, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

AVITA MED INC CDI (AVHHL) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

AVITA MED INC CDI (AVHHL) reported a net loss of $48.6M while operations used $31.2M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

AVITA MED INC CDI (AVHHL) reported an operating loss of $42.5M against $5.0M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.